Ruti Aga: Six-Year Ban for Fake Prescription Effectively Ends the Career of the 32-Year-Old Marathon Runner

Ethiopian marathon runner Ruti Aga has been banned for six years by the Athletics Integrity Unit (AIU). The sanction is built from two distinct violations—two years for the presence of the prohibited substance methylprednisolone in an in-competition sample, and four years for tampering after she submitted a forged prescription during the investigation. Together they make six years, deemed to run from 10 September of last year, when Aga was provisionally suspended. At 32, the ban removes her entirely from the 2028 Olympic cycle, and even if she returned it would be at roughly 38, at which age—given the depth of Ethiopian women's marathoning—there is no realistic route back into the national team. In other words, it is technically a six-year ban but functionally a lifetime one. The case begins with a half marathon in China last March, which Aga won. A sample taken after that race was positive for methylprednisolone. An important technical clarification is essential here, because early reports described it as a 'prohibited steroid,' which is incorrect. Methylprednisolone is a glucocorticoid, falling under category S9 of the WADA Prohibited List, not an anabolic steroid (category S1). Under the current List, S9 glucocorticoids are prohibited only in-competition, and only by injection, oral or rectal routes. This means a therapeutic glucocorticoid injection into the knee out of competition is entirely legal; it becomes a violation only if residues are present in-competition. The root of this case, therefore, is not the class of substance but the route of administration and the timing relative to competition. In road racing the testing window opens at 23:59 the day before the race, so an injection given days earlier can still be caught. Aga's defence was that the injection was given to treat a knee injury. Medically this is entirely plausible—intra-articular or peri-articular methylprednisolone for knee inflammation is standard sports-medicine practice in distance runners. The problem is that if the treatment had genuinely occurred and been properly documented, it could have been proven with real records. What Aga did instead destroyed that credibility completely. The AIU investigation found that the 'doctor' who issued the prescription was a family member with no medical registration. He claimed to have used an 'old prescription pad from a former workplace,' but the clinic named on the prescription stated explicitly that it had no connection to any such person or pad—the clinic did not in fact exist. Three independent verification failures: the clinic did not exist, the issuer was not a registered physician, and the prescription pad was disowned by the clinic. This is not merely an athlete's mistake but a signal of systemic medical-governance failure in East African road-running entourages. An athlete with a credentialed team physician would either apply for a Therapeutic Use Exemption (TUE) or observe WADA's route-specific washout rules. In Aga's case neither happened; instead the route of fabricating documents was chosen. This suggests the knee problem was likely chronic and career-long rather than an acute event that emerged in March—a repeated pattern of informal treatment may have developed, culminating in an attempt to manufacture a paper trail. A similar risk is common across East African training groups, where injured marathoners face pressure to mask pain to protect appearance-fee income, and glucocorticoids are the cheapest and most accessible tool. The arithmetic of the sanction also tells a story. The two-year ban for the presence violation is consistent with a substance in the 'Specified' category where intent was not proven; the four years for tampering is the Code's standard provision. Their combination indicates the panel rejected relief such as 'no significant fault,' which could otherwise have reduced the presence sanction. The irony is that forged documents are themselves circumstantial evidence of concealment intent, yet did not escalate the presence sanction—the panel treated the two separately. Counting the provisional suspension period toward the ban is technically a procedural benefit, not a real reprieve. From a career perspective, Aga's record is that of a genuinely top-tier marathoner. She has the 2026 Tokyo Marathon title and three second-place finishes at World Marathon Majors. Her personal bests are around 2:18:34 (Berlin 2026, second) and 2:20:40 (Tokyo 2026, first). The violation is tied to a later race, so unless earlier use is found, results before that date—including the 2026 title—are not automatically annulled, although the report does not specify the scope of disqualification. Under standard AIU practice, the result and prize money of the competition where the sample was collected should be voided, meaning her Chinese half marathon win and its prize money are likely forfeited, along with ranking points accrued thereafter. But her place in the sport's history is now split in two: on one side the 2026 Tokyo title and three Major podiums, on the other a six-year ban that makes her commercially almost untouchable in a distance-running sponsorship market that is already thin. The impact on the competitive landscape is close to zero. Ethiopia's women's marathon depth is so great that even after world-record-class runners, a 2:18-class athlete is not automatically selected for the national team. Aga has no global championship medals; her three Major second places were commercial-tier results, not championship conversions. So the absence of a 32-year-old runner does not change Ethiopia's medal capacity by any measurable margin. The real concern is sporting governance and the integrity regime. The clustering of tampering charges in recent AIU road-racing cases shows the enforcement frontier has shifted from 'detection' to 'document verification.' Aga's case is not isolated but part of a family of East African road-racing cases where an initial substance violation is compounded by a fabricated or altered explanation. Similarly, China's label-race circuit has now become a high-scrutiny zone: the intersection of large appearance-fee budgets, deep East African elite fields and AIU testing raises integrity risk in results at this tier. From a rules perspective, the sanction is standard, not exceptional, and that is its biggest lesson. Because S9 glucocorticoids are prohibited only in-competition, Aga had a legitimate defence pathway—timing, route and medical necessity could have been argued with proper documentation, potentially reducing the sanction substantially on a 'no fault' or 'no significant fault' basis, and no tampering charge would have arisen at all. But by fabricating a prescription she destroyed the one defence that could have worked. The family member being the 'doctor' is not a mitigating but an aggravating fact—it shows the athlete had no structure of credentialed medical support at all. Further risks are clear. Forged documents also open a criminal dimension outside AIU jurisdiction; referral to national authorities is possible. An appeal to CAS (generally within about 21 days of the reasoned decision) remains open to the athlete, but overturning a document-based forgery finding is difficult. Meanwhile a major question remains unanswered: whether the associates or agents who helped create or accepted the forged document were investigated. The AIU statement names only the family member, not the athlete's team or management. And no national-level statement came from the Ethiopian federation. Ultimately, the case leads to a question uncomfortable for sports policy: a six-year ban for a substance with no proven endurance benefit will be cited in both directions—as evidence of AIU rigour and as evidence of inconsistent enforcement against African road runners. The truth is that the sanction is not for the substance but for the lie. Medically appropriate treatment, at the right time, with the right paperwork, would never have given birth to this case at all.